What Older Americans Need to Know About Taking Paxlovid
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
The independent source for health policy research, polling, and news.
301 - 320 of 1,292 Results
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
This year’s JPMorgan confab, the first since covid’s chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
As flexible treatment options spurred by the covid pandemic wane, patients relying on medications classified as controlled substances worry that without action to extend the loosened rules, it’ll be harder to get their meds.
This strategy — now in place in at least 10 states — is part of an effort to curb accidental opioid overdose deaths by patients who take these powerful medications.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
KHN gives readers a chance to comment on a recent batch of stories.
Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote — such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN’s Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.
Some people say it’s reasonable for densely populated areas to receive more settlement funds, since they serve more of those affected. But others worry this overlooks rural communities disproportionately harmed by opioid addiction.
Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
KHN senior correspondent Angela Hart discussed the most pressing health care issues in California with the nonpartisan group Democracy Winters in mid-November, touching on a variety of issues, from the state’s effort to transform its Medicaid program to its plan to produce generic insulin.
The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.
KHN gives readers a chance to comment on a recent batch of stories.
© 2026 KFF